CClinicalTrials.gg
CompletedNCT07573020ADMUpdated May 7, 2026

Influence of Acellular Dermal Matrix on Peri-implant Soft Tissue Phenotype and Marginal Bone Loss

An interventional study of Polytetrafluoroethylene coverage and Acellular Dermal Matrix in Immediate Dental Implant Placement, Dental Implant and Acellular Dermal Matrix, sponsored by Mansoura University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Mansoura University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Apr 2025, registered May 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To evaluate soft tissue augmentation using acellular dermal matrix (ADM) over immediately placed dental implants in anterior maxilla.

Read the detailed description

This randomized clinical trial was designed to evaluate and compare the efficacy of ADM versus d-PTFE membranes in the preservation of the peri-implant hard and soft tissues in the setting of immediate implant placement on the anterior maxilla.

02

Conditions studied

  • Immediate Dental Implant Placement
  • Dental Implant
  • Acellular Dermal Matrix
  • Polytetrafluoroethylene
  • Soft Tissue Augmentation at Dental Implants

Keywords

  • Acellular Dermal Matrix
  • Immediate Dental Implants
  • Soft-tissue augmentation
  • Tissue Phenotype
  • d-PTFE
03

In context

Lead sponsor

Mansoura University is the lead sponsor of 1,077 studies on the registry; 183 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with non-restorable maxillary anterior tooth/teeth.
  • Good oral hygiene.
  • Patients' cooperation and fully capable to comply with the study protocol.
  • Age ranges from 18 to 45 years.
  • Free from history of parafunctional habits e.g. clenching and bruxism
  • Sufficient inter- arch space.

Exclusion criteria

Exclusion Criteria:

  • Any local pathological condition that contraindicates implant placement.
  • Pregnancy.
  • Medication that affects bone healing.
  • Psychological problems.
  • Patient had undergone radiation therapy to the head and neck area in the past 12 months.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Control Group

    Immediately placed dental implants with high-density polytetrafluorethylene membrane coverage

    Procedure: Polytetrafluoroethylene coverage

  • Experimental
    Test Group

    Immediately placed dental implants with acellular dermal matrix allograft coverage

    Procedure: Acellular Dermal Matrix

Interventions

  • ProcedurePolytetrafluoroethylene coverage

    The socket with immediately placed dental implant was covered with a d-PTFE membrane cut to fit the surgical site

  • ProcedureAcellular Dermal Matrix

    The socket with immediately placed dental implant was covered with ADM that was inserted into facial and palatal split thickness pouches.

06

What researchers measure

Primary outcomes

  1. Peri-implant soft-tissue phenotype

    A standardized periodontal probe was used to clinically measure the keratinized mucosal width, supracrestal tissue height, and mucosal thickness. They were measured in millimeters (mm)

    Time frame: Six months following implant placement

07

Study locations

1 site
  • Faculty of Dentistry - Mansoura University
    Al Mansurah, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07573020
Lead sponsor
Mansoura University
Responsible party
Sponsor
First posted
May 7, 2026
Start date
Apr 1, 2025
Primary completion
Dec 1, 2025
Completion
Mar 1, 2026
Last update
May 7, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion